Phase 3Active, not recruiting

Oral Pyridoxal 5'-Phosphate for the Treatment of Patients With PNPO Deficiency (MEND-PNPO)

Study of Pyridoxal 5'-Phosphate for the Treatment of Patients With PNPO Deficiency

Sponsor
Medicure (Industry)
Enrollment
15 planned
Conditions
Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency
Interventions
Pyridoxal Phosphate
Ages
children, adults, older adults
Registry
NCT04706013

Full record on ClinicalTrials.gov

From the registry

The proposed clinical study is intended to evaluate oral P5P for the treatment of patients confirmed to have Pyridox(am)ine 5'-Phosphate Oxidase (PNPO) deficiency via genetic analysis. There is an unmet clinical need for pharmaceutical grade P5P, as to date none has been made commercially available. Patients will receive pharmaceutical grade P5P according to their normal oral P5P dosing regimen, as previously established by their physicians.

Primary outcomes

  • Overall survival time (time to death), including incidence of death at 12 months

History

  1. Primary completion expected

  2. Last registry update

  3. Started

  4. Registered